title: IDH-Mutant Tumors Vulnerable to PARP Inhibition.
abstract: Several cancers, including glioma and acute myeloid leukemia, carry mutations inIDH1orIDH2Researchers have found that these mutations impair homologous recombination, making the tumors sensitive to PARP inhibition. They showed that one such inhibitor, olaparib, killedIDH1/2-mutant cancer cells in culture and slowed tumor growth in mice.
mesh_terms: D000818:Animals; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D059765:Homologous Recombination / Q000235:genetics; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D051379:Mice; D009154:Mutation; D010793:Phthalazines / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000008:administration & dosage*; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human; D011065:Poly(ADP-ribose) Polymerases; C531550:olaparib